Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.45 |
| ▸ | MT-CO2 | P00403 | 2/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.44 |
| ▸ | GPR6 | P46095 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.42 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577752 | 0.97 | MT-CO2 (0.47) | EPHX2MT-CO2GPR6TP53MAPK8 | |
| SCHEMBL5577253 | 0.88 | P2RX7 (0.44) | P2RX7EPHX2PIK3CDTP53LMNA | |
| SCHEMBL5577826 | 0.86 | MT-CO2 (0.49) | MT-CO2KDM4EMAPT | |
| SCHEMBL5577874 | 0.85 | MT-CO2 (0.44) | MT-CO2PIK3CDGPR6TP53KDM4E | |
| SCHEMBL5577376 | 0.84 | MAPK8 (0.43) | P2RX7MT-CO2TP53MAPK8 | |
| SCHEMBL5577589 | 0.84 | MT-CO2 (0.43) | P2RX7EPHX2MT-CO2TP53MAPK8 | |
| SCHEMBL5577621 | 0.84 | LMNA (0.47) | EPHX2TP53LMNAALDH1A1KDM4E | |
| SCHEMBL5577844 | 0.84 | SCN10A (0.56) | EPHX2SCN2ASCN10AKDM4E | |
| SCHEMBL5577531 | 0.84 | MT-CO2 (0.54) | MT-CO2TP53LMNAKDM4EMAPT | |
| SCHEMBL5577406 | 0.84 | MT-CO2 (0.47) | MT-CO2PIK3CDKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1616862-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | P2RX7 1272/4885EPHX2 1772/4885MT-CO2 2047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.